Novartis India board reconstituted after ChrysCapital takeover completes

CFO resignedMultiple independent directors resignedKey managerial personnel resignedDirector resignedManagement Changes View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1600.00

prior close

₹1610.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.6-0.4-0.7-0.3

Next day

-2.4+0.5-2.9-0.5-1.9

+2.8+1.9+0.9+0.2+2.6

+1.8+2.3-0.5+0.1+1.7

+2.3+3.6-1.4+0.5+1.8

-0.1+4.0-4.1+0.7-0.8

+0.2+4.0-3.7+1.4-1.2

15d

-7.3+4.9-12.2+0.4-7.7

-1.6+5.9-7.5+1.7-3.3

+19.7+4.8+14.9+2.7+17.0

+7.8pendingpending-3.1+10.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Novartis AG sold 1.74 crore shares (about 70 percent stake) to ChrysCapital group entities (WaveRise, Fund X, TIP), completing change of control. Novartis AG ceases to be promoter and is reclassified as public. 6 directors resigned, including Chairperson Christopher Snook, CFO Shilpa Joshi, and 3 independent directors. 6 new directors appointed, with ChrysCapital nominees and 3 new independent directors joining the board.

Likely market impact

Major ownership change complete. Old Novartis-nominee board replaced. ChrysCapital now controls the company. Watch for strategic shifts under new management.